HutchMED (China) LIMITED Research and Development Expense
HutchMED (China) LIMITED (HMDCF) reported Research and Development Expense of $148.29 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-05
- HutchMED (China) LIMITED research and development expense for the quarter ending 2019-12-31 was $37.45M, a 47.29% increase year-over-year.
- HutchMED (China) LIMITED research and development expense for the quarter ending 2019-09-30 was $31.45M, a 9.66% increase year-over-year.
- HutchMED (China) LIMITED research and development expense for the quarter ending 2019-06-30 was $36.01M, a 14.71% increase year-over-year.
- HutchMED (China) LIMITED research and development expense for the quarter ending 2019-03-31 was $33.28M, a 16.11% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $148.29M 20-F · filed 2026-03-05 | |||
| 2025-06-30 | $71.99M 6-K · filed 2025-08-07 | |||
| 2024-12-31 | $212.11M 20-F · filed 2026-03-05 | |||
| 2024-06-30 | $95.26M 6-K · filed 2025-08-07 | |||
| 2023-12-31 | $302.00M 20-F · filed 2026-03-05 | |||
| 2023-06-30 | $144.63M 6-K · filed 2024-07-31 | |||
| 2022-12-31 | $386.89M 20-F · filed 2025-03-19 | |||
| 2022-06-30 | $181.74M 6-K · filed 2023-07-31 | |||
| 2021-12-31 | $299.09M 20-F · filed 2024-02-28 | |||
| 2021-06-30 | $123.05M 6-K · filed 2022-08-01 | |||
| 2020-12-31 | $174.78M 20-F · filed 2023-02-28 | |||
| 2020-06-30 | $73.97M 6-K · filed 2021-07-28 | |||
| 2019-12-31 | $37.45M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-03 | $68.90M derived: sum of 2 quarters · filed 2022-03-03 | $104.91M derived: sum of 3 quarters · filed 2022-03-03 | $138.19M 20-F · filed 2022-03-03 |
| 2019-09-30 | $31.45M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $67.45M derived: sum of 2 quarters · filed 2020-07-30 | $100.73M 6-K · filed 2020-01-21 | $126.16M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-06-30 | $36.01M derived: 6-K 6 month − 6-K 3 month · filed 2020-07-30 | $69.29M 6-K · filed 2020-07-30 | $94.72M derived: sum of 3 quarters · filed 2021-03-04 | $123.39M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-03-31 | $33.28M 6-K · filed 2019-06-06 | $58.71M derived: sum of 2 quarters · filed 2021-03-04 | $87.39M derived: sum of 3 quarters · filed 2021-03-04 | $118.78M derived: sum of 4 quarters · filed 2021-03-04 |
| 2018-12-31 | $25.43M derived: 20-F 12 month − 6-K 9 month · filed 2021-03-04 | $54.11M derived: sum of 2 quarters · filed 2021-03-04 | $85.50M derived: sum of 3 quarters · filed 2021-03-04 | $114.16M 20-F · filed 2021-03-04 |
| 2018-09-30 | $28.68M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $60.07M derived: sum of 2 quarters · filed 2020-01-21 | $88.73M 6-K · filed 2020-01-21 | |
| 2018-06-30 | $31.39M derived: 6-K 6 month − 6-K 3 month · filed 2019-07-30 | $60.05M 6-K · filed 2019-07-30 | ||
| 2018-03-31 | $28.66M 6-K · filed 2019-06-06 | |||
| 2017-12-31 | $75.52M 20-F · filed 2020-03-03 | |||
| 2017-06-30 | $31.57M 6-K · filed 2018-07-27 | |||
| 2016-12-31 | $66.87M 20-F · filed 2019-03-11 | |||
| 2016-06-30 | $31.18M 6-K · filed 2017-07-31 | |||
| 2015-12-31 | $47.37M 20-F · filed 2018-03-12 | |||
| 2014-12-31 | $29.91M 20-F · filed 2017-03-13 |